TDO2 and neoplasm: They showed the expression of TDO rather than IDO1 in tumor cells, and its strong association with Kyn expression, but also with forkhead box P3 expression, as well as its association with tumor progression, with ICIs suggesting its potential as a predictive biomarker of resistance to ICIs in patients with mRCC.